INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,715,056 | -7.1% | 320,888 | +13.0% | 0.02% | -4.5% |
| Q2 2023 | $17,985,349 | +76.3% | 284,039 | +50.8% | 0.02% | +57.1% |
| Q1 2023 | $10,202,726 | +186.3% | 188,416 | +179.8% | 0.01% | +180.0% |
| Q4 2022 | $3,563,844 | -99.9% | 67,344 | +25.4% | 0.01% | +25.0% |
| Q3 2022 | $2,499,312,000 | +2.7% | 53,714 | +26.0% | 0.00% | 0.0% |
| Q2 2022 | $2,432,978,000 | +97.5% | 42,624 | +111.7% | 0.00% | +100.0% |
| Q1 2022 | $1,231,938,000 | +57.5% | 20,133 | +34.7% | 0.00% | +100.0% |
| Q4 2021 | $782,169,000 | +65.8% | 14,944 | +18.1% | 0.00% | 0.0% |
| Q3 2021 | $471,741,000 | +336.4% | 12,654 | +377.9% | 0.00% | – |
| Q2 2021 | $108,091,000 | -84.3% | 2,648 | -87.0% | 0.00% | -100.0% |
| Q1 2021 | $689,322,000 | +67.2% | 20,316 | +56.7% | 0.00% | 0.0% |
| Q4 2020 | $412,287,000 | +4.4% | 12,965 | -15.8% | 0.00% | 0.0% |
| Q3 2020 | $394,882,000 | +334.1% | 15,389 | +334.2% | 0.00% | – |
| Q2 2020 | $90,974,000 | -65.2% | 3,544 | -79.2% | 0.00% | -100.0% |
| Q1 2020 | $261,751,000 | +22.4% | 17,030 | +173.2% | 0.00% | – |
| Q4 2019 | $213,854,000 | +252.6% | 6,233 | -23.2% | 0.00% | – |
| Q3 2019 | $60,656,000 | -22.4% | 8,120 | +34.9% | 0.00% | – |
| Q2 2019 | $78,127,000 | -38.1% | 6,019 | -41.9% | 0.00% | – |
| Q1 2019 | $126,197,000 | +951.2% | 10,361 | +883.0% | 0.00% | – |
| Q4 2018 | $12,005,000 | -78.4% | 1,054 | -58.9% | 0.00% | – |
| Q3 2018 | $55,682,000 | +32.7% | 2,566 | +8.1% | 0.00% | – |
| Q2 2018 | $41,949,000 | -77.2% | 2,374 | -72.8% | 0.00% | – |
| Q1 2018 | $183,956,000 | +13.3% | 8,739 | -22.0% | 0.00% | – |
| Q4 2017 | $162,321,000 | +145.1% | 11,210 | +167.2% | 0.00% | – |
| Q3 2017 | $66,213,000 | +20.1% | 4,196 | -5.5% | 0.00% | – |
| Q2 2017 | $55,132,000 | +348.8% | 4,439 | +487.2% | 0.00% | – |
| Q1 2017 | $12,285,000 | -25.7% | 756 | -31.0% | 0.00% | – |
| Q4 2016 | $16,539,000 | -71.3% | 1,096 | -71.1% | 0.00% | – |
| Q3 2016 | $57,714,000 | +11.9% | 3,787 | +185.0% | 0.00% | – |
| Q2 2016 | $51,592,000 | -80.7% | 1,329 | -73.3% | 0.00% | -100.0% |
| Q4 2015 | $267,874,000 | +48.0% | 4,980 | +10.2% | 0.00% | – |
| Q3 2015 | $181,021,000 | +213.9% | 4,521 | +150.5% | 0.00% | – |
| Q2 2015 | $57,670,000 | +506.8% | 1,805 | +353.5% | 0.00% | – |
| Q1 2015 | $9,504,000 | -32.2% | 398 | -61.1% | 0.00% | – |
| Q3 2014 | $14,025,000 | – | 1,023 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |